跳到正文
原文
Medical Xpress·· 28 天前精选AI 评分64

瑞典登记研究:多发性硬化患者使用 rituximab 与炎症性肠病风险升高相关

Common multiple sclerosis treatment linked to bowel disease risk

AI 导读

一项基于瑞典登记数据、覆盖近1.4万个治疗疗程的研究显示,多发性硬化患者使用 rituximab 后发生炎症性肠病的风险约为其他三种高效治疗的10倍,但10年内绝对风险低于2%。

推荐理由

基于瑞典登记数据近1.4万个治疗疗程的分析,为抗CD20治疗与炎症性肠病的关联提供了绝对风险量级参考。

正文
Common MS treatment linked to bowel disease risk
Crude and Adjusted Survival Curves for Time to Inflammatory Bowel Disease, Stratified by Exposure Group. Credit: JAMA Neurology (2026). DOI: 10.1001/jamaneurol.2026.3439

People with multiple sclerosis (MS) who are treated with rituximab have an increased risk of developing inflammatory bowel disease, particularly Crohn's disease, although the absolute risk remains low. This is according to the first large population-based study in the field, led by researchers at Karolinska Institutet and published in JAMA Neurology.

Rituximab belongs to a group of drugs known as anti-CD20 therapies and is currently the most used disease-modifying treatment for MS in Sweden. As the use of anti-CD20 therapies has increased, cases of inflammatory bowel disease have been reported among patients receiving these treatments, raising concerns among neurologists. Until now, however, evidence from large studies has been lacking. The new study is the first population-based study to systematically investigate the association.

The researchers analyzed nearly 14,000 treatment episodes among people with relapsing-remitting MS, using data from Swedish registers. They compared rituximab with three other highly effective MS treatments: natalizumab, dimethyl fumarate and fingolimod.

Inflammatory bowel disease was more common among people treated with rituximab than among those receiving any of the other three treatments, even after differences in follow-up time were taken into account. After adjusting for other differences between the groups, the researchers found that the risk was around 10 times higher with rituximab than with the other MS treatments.

Few patients developed the disease

Despite the increased relative risk, the absolute risk remained low. Fewer than 2% of patients in any of the treatment groups developed inflammatory bowel disease within 10 years of starting treatment. The increase in risk corresponded to approximately one additional case for every 131 patients treated with rituximab for five years rather than with one of the other treatments. Most of the cases were Crohn's disease.

"This is the first large study to quantify the risk of inflammatory bowel disease associated with anti-CD20 treatment for MS. The results show that this is a potential adverse effect that should be considered when choosing an MS treatment. At the same time, the increased risk needs to be weighed against the benefits for the individual patient. Anti-CD20 drugs are among the most effective treatments for preventing MS relapses," says Peter Alping, a researcher at the Department of Medicine, Solna, and last author of the study.

Publication details

Sandra Kallin et al., Risk of Inflammatory Bowel Disease After Anti-CD20 Treatment in Multiple Sclerosis, JAMA Neurology (2026). DOI: 10.1001/jamaneurol.2026.3439

Journal information: Archives of Neurology

Who's behind this story?

Gaby Clark

Gaby Clark

MA in English, copy editor since 2021 with experience in higher education and health content. Dedicated to trustworthy science news. Full profile →

Robert Egan

Robert Egan

Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →

Citation: Common multiple sclerosis treatment linked to bowel disease risk (2026, October 22) retrieved 22 October 2026 from https://medicalxpress.com/news/2026-10-common-multiple-sclerosis-treatment-linked.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

来源:Medical Xpress · medicalxpress.com